Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth**: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).
From Akums Drugs & Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- **Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.
- **Domestic Formulations:** Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%.
- **CDMO Business:** Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices.
- **Export Business:** Base branded export business expected to grow at high double digits (~20%+) over next 2-3 years.
- **API Business:** Planning ~10% volume growth but revenues and profits dependent on Cephalosporin prices. Losses targeted to reduce but breakeven likely only by FY '27.
- **Capacity Planning:** Capacity utilization currently ~31-38%, with plans to enhance production for growth in oral solids and injectables.
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex.
- Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms.
- EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract.
- New product facility being set up at Baddi 1 (A 11) for serving European markets.
- Strategy includes adding capacity with foresight of 24 months due to plant validation timelines.
- Capacity expansions are spread across dosage forms, including injectables, oral solids, oral liquids, oncologics, and steroids.
- M&A opportunities actively explored, primarily in CDMO and export businesses, focusing on profitable and synergistic entities.
- The INR 1,000+ crores cash on books is partly earmarked but can be used for strategic investments or acquisitions.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025).
- This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue.
- The European contract marks entry into about 20 countries.
- The business related to this contract falls under the CDMO segment, targeting similar margins (approximately 15%-20%).
- For the base export branded business excluding the large European contract, the company expects high double-digit (around 20%) growth over the next 2 to 3 years.
- No specific mention of other pending orderbooks or backlog figures was made.
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules Ltd (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q4 FY25 results?
Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth**: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex. - Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms. - EUR 20 million (approx.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.